Beijing Biosis Healing Biological Technology Co., Ltd. has recently harvested the good news. The "industrialization of implantable regenerative extracellular matrix source biomaterials and series of products" project has been rated as "transformation and industrialization project of major cutting-edge original technology achievements" by the Zhongguancun Demonstration Park High-tech Industry Development Project.
In June 2018, in order to implement the instructions of Beijing Municipal and municipal government, Zhongguancun Science and Technology Park issued a notice on the application of the “transformation and industrialization project of major cutting-edge original technology achievements” project for the cultivation of high-tech industries, to support the development of several key industries. Among them, Zhongguancun National Innovation Demonstration Zone Development and Construction Plan (2016-2020), "R&D Directions for Key Technologies in Emerging Industries" clearly included key technologies for new planting intervention materials.
Extracellular matrix source materials are the development direction of tissue - induced biomedical materials
The non-crosslinked extracellular matrix source materials are represented by porcine small intestinal submucosa (SIS) materials. The material adopts the animal small intestine submucosal tissue as a raw material, removes the immunogenicity and other risks, retains The three-dimensional structure and components of the natural extracellular matrix. The material
can actively induce cell regeneration and repair after implantation in the body and realize tissue functional regeneration. It can be completely degraded in vivo and has the advantages of resistance to infection and anti-adhesion. The material can be used for the regeneration and repair of almost all soft tissues of the human body. It is the only regenerative medicine material with platform properties.
At present, the application of this material product penetrates into various subdivisions of clinical surgery, and has been widely used in abdominal surgery, gastrointestinal surgery, ENT, urology, obstetrics and gynecology, chest surgery, neurosurgery, stomatology, orthopedics, first aid for war trauma and other important surgical fields, realizes the regeneration and repair of various soft tissues of the human body, and are replacing the traditional polymer material market.
This project serves as a major cutting-edge basic research achievement in the 863 Key Special Project in New Materials in the 12th Five-Year Plan of the Ministry of Science and Technology of China
This project focuses on the field of surgical repair, focuses on the development of core technology of SIS materials and solves the key core problems of industrialization of SIS materials. It is aimed at abdominal wall repair, dura mater defect repair, anastomotic stoma reinforcement, tympanic membrane reconstruction, peripheral nerve injury repair, war injury first-aid, endometrial repair, tendon injury repair, refractory wound healing, urinary system repair, infectious sinus repair and other clinical needs. Developed independent III intellectual property rights implanted device products provide a series of solutions for tissue repair after surgical resection and functional regeneration.
The basic and pre-clinical research of this project was established as the sub-project of the 2015 National High-Tech Research and Development Plan (863 Program), cutting-edge technology key project in the field of new materials, "Research and Development of Highly Plastic Controllable Degradable Implant Materials" (Project Number: 2015AA033600), "Xenogeneic acellular matrix material for human implantation" (Subject No. 2015AA033602) . The preclinical research was also supported by the 2014 Science and Technology Small and Medium Enterprise Promotion Fund of the Beijing Municipal Science and Technology Commission (Z14010101281) and the 2014 Beijing Science and Technology Commission's Innovative Clinical Research Project (Z151100003915055).
The research of high-performance medical biomaterials and the development of high-end medical device products have always been the development direction of the global health industry. The new industries of biomedical materials and implanted devices with high induction activity, controlled degradation, and promotion of repair and regeneration will become the main body of the future biomedical materials industry. Therefore, the implementation of this project will form a key common technical system for organizing and inducing the industrialization of biomedical materials with independent intellectual property rights. It will launch a series of fully domestically produced tissue repair implantable medical devices with high quality and low price, and enter the international market, so that better regenerative medical materials benefit more patients.
版权所有®2019BIOSISHEALING